| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Mitoquinone mesylate (also known as MITOQ; MitoQ or MitoQ10), the mesylate salt of Mitoquinone, is a novel and potent TPP-based, mitochondrially targeted antioxidant designed to accumulate within mitochondria in vivo in order to protect against oxidative damage. MitoQ comprises a positively charged lipophilic cation that drives its extensive accumulation within the negatively charged mitochondria inside cells. The active antioxidant component of MitoQ is ubiquinone, which is identical to the active antioxidant in Coenzyme Q10. It is this approximately thousand-fold greater concentration of MitoQ within mitochondria that makes it more effective at preventing mitochondrial oxidative damage when compared to untargeted antioxidants such as Coenzyme Q10. NOTE: For the convenience of use, this product is supplied as 200mg /mL solution in ethanol-water (1:1, v/v) solution since pure MitoQ10 is a tar-like or waxy semi-solid and very hard to transfer between containers.
| ln Vitro |
Mitoquinone (MitoQ) is an antioxidant that targets mitochondria. During four hours of cold storage (CS), dose-response tests were used to determine the ideal dosages of mitoquinone (MitoQ) and DecylTPP therapy. In order to investigate the potential protective impact of mitoquinone treatment on CS damage, MitoSOX Red—a fluorescent dye that targets and detects mitochondrial superoxide production—was first used. When CS was applied to normal rat kidney (NRK) cells, mitochondrial superoxide caused the cells' fluorescence to increase by about two times when compared to the control group. When it came to CS-induced mitochondrial superoxide production, quinone from mitochondria significantly defended against it, while DecylTPP, the control chemical, had no such effect. Treatment for mitochondrial superoxide greatly decreased the generation of mitochondrial superoxide, and kidneys treated with DecylTPP had levels of mitochondrial superoxide that were on par with kidneys receiving CS alone [1].
|
|---|---|
| ln Vivo |
Treatment with mitoquinone (MitoQ) dramatically decreased neutrophil infiltration and pancreatic edema. Serum amylase is dose-dependently increased by MitoQ; at higher doses, it roughly doubles. When administered at 10 mg/kg (dose 1), MitoQ treatment dramatically raised serum IL-6 levels and nearly doubled Caerulein-induced lung MPO activity [2].
|
| References |
[1]. Mitchell T, et al. The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renaltubular cells and rat kidneys. J Pharmacol Exp Ther. 2011 Mar;336(3):682-92.
[2]. Huang W, et al. Effects of the mitochondria-targeted antioxidant mitoquinone in murine acute pancreatitis. Mediators Inflamm. 2015;2015:901780 |
| Molecular Formula |
C38H47O7PS
|
|---|---|
| Molecular Weight |
678.8144
|
| CAS # |
845959-50-4
|
| Related CAS # |
845959-50-4 (mesylate);845959-52-6 (beta-CD complex);444890-41-9 (cation);336184-91-9 (bromide);
|
| SMILES |
O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4C)C(OC)=C(OC)C4=O.CS(=O)([O-])=O
|
| InChi Key |
GVZFUVXPTPGOQT-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C37H44O4P.CH4O3S/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32;1-5(2,3)4/h10-18,21-26H,4-9,19-20,27-28H2,1-3H3;1H3,(H,2,3,4)/q+1;/p-1
|
| Chemical Name |
(10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl)triphenylphosphonium methanesulfonate
|
| Synonyms |
Mito Q10; Mitoquinone methanesulfonate; MitoQ; MitoQ10 mesylate; MitoQ mesylate; MitoQ10; MitoQ-10;
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~147.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.68 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 7.69 mg/mL (11.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4732 mL | 7.3658 mL | 14.7317 mL | |
| 5 mM | 0.2946 mL | 1.4732 mL | 2.9463 mL | |
| 10 mM | 0.1473 mL | 0.7366 mL | 1.4732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Effect of MitoQ on mitochondrial superoxide generation during CS.
Effect of MitoQ on CS-induced renal injury and cell death.J Pharmacol Exp Ther.2011 Mar;336(3):682-92. |
|---|
 MitoQ attenuates nitrotyrosine formation during CS.
MitoQ decreases CS plus RW oxidant production and cell death.J Pharmacol Exp Ther.2011 Mar;336(3):682-92. |
 MitoQ prevents mitochondrial respiratory complex inactivation during CS.Individual mitochondrial respiratory complex activities were measured using isolated mitochondria from NRK cells (A and B) and isolated rat kidney mitochondria (C-F) exposed to CS, CS + MitoQ, or CS + DecylTPP (1 μM in vitro and 100 μM ex vivo). Values are expressed as percentage mean ± S.E.M. (n= 3 in vitro or 5 ex vivo) of respective controls (set to 100). **,P< 0.01 or ***,P< 0.001 compared with respective controls. †,P< 0.05 compared with CS.J Pharmacol Exp Ther.2011 Mar;336(3):682-92. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
